Department of Radiation Oncology, University of Arizona, Tucson, AZ 85724, USA.
BMC Cancer. 2012 May 11;12:175. doi: 10.1186/1471-2407-12-175.
To evaluate the feasibility of image-guided radiotherapy based on helical Tomotherapy to spare the contralateral parotid gland in head and neck cancer patients with unilateral or no neck node metastases.
A retrospective review of 52 patients undergoing radiotherapy for head and neck cancers with image guidance based on daily megavoltage CT imaging with helical tomotherapy was performed.
Mean contralateral parotid dose and the volume of the contralateral parotid receiving 40 Gy or more were compared between radiotherapy plans with significant constraint (SC) of less than 20 Gy on parotid dose (23 patients) and the conventional constraint (CC) of 26 Gy (29 patients). All patients had PTV coverage of at least 95% to the contralateral elective neck nodes. Mean contralateral parotid dose was, respectively, 14.1 Gy and 24.7 Gy for the SC and CC plans (p < 0.0001). The volume of contralateral parotid receiving 40 Gy or more was respectively 5.3% and 18.2% (p < 0.0001)
Tomotherapy for head and neck cancer minimized radiotherapy dose to the contralateral parotid gland in patients undergoing elective node irradiation without sacrificing target coverage.
评估基于螺旋断层放疗的图像引导放疗在单侧或无颈部淋巴结转移的头颈部癌症患者中保护对侧腮腺的可行性。
回顾性分析了 52 例接受基于每日兆伏 CT 成像的螺旋断层放疗的头颈部癌症放疗的患者。
与腮腺剂量的显著约束(SC)<20 Gy(23 例)和常规约束(CC)26 Gy(29 例)的放疗计划相比,比较了腮腺剂量为 40 Gy 或以上的对侧腮腺平均剂量和对侧腮腺接受 40 Gy 或以上的体积。所有患者的对侧选择性颈部淋巴结的 PTV 覆盖率至少为 95%。SC 和 CC 计划的对侧腮腺平均剂量分别为 14.1 Gy 和 24.7 Gy(p<0.0001)。对侧腮腺接受 40 Gy 或以上的体积分别为 5.3%和 18.2%(p<0.0001)。
在接受选择性淋巴结照射的患者中,螺旋断层放疗对头颈部癌症的治疗可将对侧腮腺的放疗剂量降至最低,而不会牺牲靶区覆盖范围。